TRAVERE THERAPEUTICS

Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

04 يونيو 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 يونيو 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

27 مايو 2021 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

25 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2021 Financial Results

06 مايو 2021 16:01:02 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

27 أبريل 2021 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2021 Financial Results

26 أبريل 2021 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

01 مارس 2021 16:01:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

25 فبراير 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

22 فبراير 2021 16:30:00 بحسب Nasdaq GlobeNewswire